IRIDEX Corporation (IRIX) announced that an educational story based on its innovative MicroPulse technology for the treatment of diabetic macular edema (DME) and age-related macular degeneration (AMD), was recently featured on the Washington, D.C. edition of “American Health Front,” a health news program focused on advances in medical techniques and technologies.
At the American Academy of Ophthalmology seminar in New Orleans, a busy booth was Iridex (Mountain View, California), which has recently been showing robust sales growth and improving profitability under the astute management of CEO Will Moore. The company, which has a sterling reputation in the ophthalmic laser space for two decades, sponsored a series of informative talks at its booth on the myriad applications for its laser products.
David Dickman, MD, of the Universal Eye Center (Rolesville, North Carolina) discussed Iridex’s 532 nm micropulse laser in a talk titled “A Comprehensive Laser for the Comprehensive Ophthalmologist: Clinical and Economical Advantages.”
MicroPulse technology is a promising, tissue-sparing laser therapy that allows the tissue to cool between laser pulses, minimizing or preventing tissue damage. Drugs injected directly into the eye have a role in treating retinal diseases, but there are serious issues in terms of costs and logistics due to the need for continuous injections for the rest of one’s life. This is just not a sustainable model in today’s value-based medicine world. MicroPulse offers powerful advantages, in terms of durability, economics and logistics for payors and patients.
For more info: